186 related articles for article (PubMed ID: 23155282)
1. Papillary-serous adenocarcinoma of the uterine cervix during tamoxifen therapy after bilateral breast cancer.
Watrowski R; Striepecke E; Jäger C; Bauknecht T; Horst C
Anticancer Res; 2012 Nov; 32(11):5075-8. PubMed ID: 23155282
[TBL] [Abstract][Full Text] [Related]
2. Ovarian low-grade serous carcinoma involving the cervix mimicking a cervical primary.
Malpica A; Deavers MT
Int J Gynecol Pathol; 2011 Nov; 30(6):613-9. PubMed ID: 21979600
[TBL] [Abstract][Full Text] [Related]
3. [Radical hysterectomy with pelvic lymphadenectomy in patients with carcinoma of the uterine cervix--3 years' experience].
Bosković V; Glisić A; Petković S
Srp Arh Celok Lek; 1998; 126(5-6):183-7. PubMed ID: 9863378
[TBL] [Abstract][Full Text] [Related]
4. Co-occurrence of atypical endometriosis, subserous uterine leiomyomata, sactosalpinx, serous cystadenoma and bilateral hemorrhagic corpora lutea in a perimenopausal adipose patient taking tamoxifen (20 mg/day) for invasive lobular breast cancer.
Ebert AD; Rosenow G; David M; Mechsner S; Magalov IS; Papadopoulos T
Gynecol Obstet Invest; 2008; 66(3):209-13. PubMed ID: 18645252
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
Gruvberger-Saal SK; Bendahl PO; Saal LH; Laakso M; Hegardt C; Edén P; Peterson C; Malmström P; Isola J; Borg A; Fernö M
Clin Cancer Res; 2007 Apr; 13(7):1987-94. PubMed ID: 17404078
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
[TBL] [Abstract][Full Text] [Related]
7. Synchronous metastasis from lobular carcinoma and primary carcinoma of the endometrium in a patient after tamoxifen therapy.
Vicioso L; Ortega MV; Cívico V; López-Beltrán A
Int J Gynecol Pathol; 2013 Jan; 32(1):66-70. PubMed ID: 23202785
[TBL] [Abstract][Full Text] [Related]
8. High-grade endometrial stromal sarcoma after tamoxifen therapy for breast cancer.
Sesti F; Patrizi L; Ermini B; Palmieri G; Orlandi A; Piccione E
Gynecol Obstet Invest; 2005; 60(2):117-20. PubMed ID: 15920338
[TBL] [Abstract][Full Text] [Related]
9. Cytokeratin 7-positive/cytokeratin 20-negative cecal adenocarcinoma metastatic to the uterine cervix: a case report.
Toyoshima M; Momono Y; Makino H; Kudo T; Oka N; Sakurada J; Suzuki H; Kodama H; Yoshinaga K
World J Surg Oncol; 2016 Jan; 14(1):22. PubMed ID: 26810414
[TBL] [Abstract][Full Text] [Related]
10. Papillary serous adenocarcinoma of the uterine cervix: a report of three cases.
Gilks CB; Clement PB
Mod Pathol; 1992 Jul; 5(4):426-31. PubMed ID: 1495949
[TBL] [Abstract][Full Text] [Related]
11. [The morphological features of the uterine body adenocarcinoma].
Dzhaparidze NA; Chakvetatdze LB; Dzhikia ID
Georgian Med News; 2014 Jun; (231):72-7. PubMed ID: 25020177
[TBL] [Abstract][Full Text] [Related]
12. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
[TBL] [Abstract][Full Text] [Related]
13. Relationship between tamoxifen use and high risk endometrial cancer histologic types.
Bland AE; Calingaert B; Secord AA; Lee PS; Valea FA; Berchuck A; Soper JT; Havrilesky L
Gynecol Oncol; 2009 Jan; 112(1):150-4. PubMed ID: 18937966
[TBL] [Abstract][Full Text] [Related]
14. Well-differentiated papillary villoglandular adenocarcinoma of the uterine cervix.
Datta CK
W V Med J; 1997; 93(4):186-8. PubMed ID: 9274143
[TBL] [Abstract][Full Text] [Related]
15. Nonproliferative epithelial alteration and expression of estrogen receptor and Ki67 in the contralateral breast of women treated with tamoxifen for breast cancer.
de Souza Sales JF; Cabello C; Alvarenga M; Torresan RZ; Duarte GM
Breast; 2007 Apr; 16(2):197-203. PubMed ID: 17178225
[TBL] [Abstract][Full Text] [Related]
16. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
17. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
Honma N; Horii R; Iwase T; Saji S; Younes M; Takubo K; Matsuura M; Ito Y; Akiyama F; Sakamoto G
J Clin Oncol; 2008 Aug; 26(22):3727-34. PubMed ID: 18669459
[TBL] [Abstract][Full Text] [Related]
18. Villoglandular papillary adenocarcinoma of the uterine cervix with immunohistochemical characteristics.
Polat A; Düsmez D; Pata O; Aydin O; Egilmez R
J Exp Clin Cancer Res; 2002 Sep; 21(3):425-7. PubMed ID: 12385589
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine carcinoma of the breast--diagnostic and clinical implications.
Watrowski R; Jäger C; Mattern D; Horst C
Anticancer Res; 2012 Nov; 32(11):5079-82. PubMed ID: 23155283
[TBL] [Abstract][Full Text] [Related]
20. [Villous glandular adenocarcinoma of the uterine cervix. A subtype with favourable prognosis?].
Reed W; Abeler VM; Tropé CG
Tidsskr Nor Laegeforen; 1993 Aug; 113(20):2569-71. PubMed ID: 8236177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
